MIT study reveals how specific cells in AD become vulnerable and resilient
The neurodegenerative condition is recognised as the most common form of dementia
Read Moreby Jen Brogan | Jul 29, 2024 | News | 0
The neurodegenerative condition is recognised as the most common form of dementia
Read Moreby Jen Brogan | Jul 25, 2024 | Uncategorized, News | 0
Conditions such as Alzheimer’s and Parkinson’s affect over one million people in the UK
Read Moreby Jen Brogan | Jul 23, 2024 | News | 0
The neurological disease is estimated to affect more than ten million people globally
Read Moreby Jen Brogan | Jul 11, 2024 | News | 0
The ESRC EquaDem Network Plus aims to improve disparities in diagnosis and care
Read Moreby Jen Brogan | Jul 8, 2024 | News | 0
The progressive neurodegenerative condition affects around 153,000 people in the UK
Read Moreby Jen Brogan | Jun 28, 2024 | News | 0
The neurodegenerative condition currently affects around 153,000 people in the UK
Read Moreby Jen Brogan | Jun 24, 2024 | News | 0
The manifesto calls on the next UK government to make dementia a key health priority
Read Moreby Jen Brogan | Apr 3, 2024 | News | 0
The progressive neurodegenerative disease is estimated to affect 24 million people globally
Read Moreby Jen Brogan | Mar 25, 2024 | News | 0
Estimated to affect 2.5 million people in the US, synucleinopathies comprise four neurodegenerative disorders
Read Moreby Jen Brogan | Dec 14, 2023 | News | 0
The collaboration aims to develop biomarker-based diagnostics for the condition
Read Moreby Jen Brogan | Dec 14, 2023 | News | 0
The free programme will be offered to those who are affected by the condition
Read Moreby Jen Brogan | Nov 24, 2023 | News | 0
The findings could benefit patients living with neurodegenerative conditions
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479